Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;88(3):711-714.
doi: 10.1016/j.jaad.2022.09.012. Epub 2022 Sep 14.

Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition

Ted V Jacoby  1 , Nishi Shah  2 , Maria S Asdourian  3 , Leah L Thompson  4 , Tracey S Otto  5 , Nicole R LeBoeuf  6 , Yevgeniy Semenov  3 , Edward Christopher Dee  7 , Kerry L Reynolds  8 , Steven T Chen  9
Affiliations

Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition

Ted V Jacoby et al. J Am Acad Dermatol. 2023 Mar.
No abstract available

Keywords: cutaneous immune-related adverse event; dermatology consultation; immune checkpoint inhibitor; immunotherapy; skin toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest STC has received honoraria from Pfizer and Novartis for serving on an advisory board for digital media. Nicole R. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Fortress Biotechnologies, Silverback, and Synox Therapeutics outside the submitted work.

References

    1. Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep. 2020;22(4):39. doi:10.1007/s11912-020-0897-9 - DOI - PubMed
    1. Reynolds KL, Arora S, Elayavilli RK, et al. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer. 2021;9(7):e002896. doi:10.1136/jitc-2021-002896 - DOI - PMC - PubMed
    1. Cho YT, Lin YT, Yang CW, Chu CY. Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit. Sci Rep. 2022;12(1):7021. doi:10.1038/s41598-022-11128-5 - DOI - PMC - PubMed
    1. Nadelmann ER, Yeh JE, Chen ST. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review. JAMA Oncol. 2022;8(1):130–138. doi:10.1001/jamaoncol.2021.4318 - DOI - PubMed